Respiratory syncytial virus vaccines

Ruth A Karron, Donna M. Ambrosino

Research output: Contribution to journalArticle

Abstract

Progress in RSV vaccine development has been rapid over the last few years. The availability of recombinant technology will allow determination of the genetic basis for attenuation of biologically derived vaccines, as well as the development of new vaccines containing novel combinations of attenuating mutations. This may hasten the identification of live viral vaccine candidates for phase III trials. Additionally, the RSV PFP-2 subunit vaccine is being considered for further phase II studies. Distinct target populations such as infants, pregnant women, the elderly, immunocompromised patients, and children with chronic lung disease may require the use of different vaccines, or combinations of vaccines. It is hoped that the recent advances described here will lead to the development of effective vaccines against this important respiratory pathogen.

Original languageEnglish (US)
Pages (from-to)919-920
Number of pages2
JournalPediatric Infectious Disease Journal
Volume17
Issue number10
DOIs
Publication statusPublished - 1998

    Fingerprint

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this